PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor.

A new document compiled by four cardiac imaging professional societies provides a resource to guide clinicians in best practices for assessing valvular regurgitation following catheter-based repair or replacement of a valve. The document, available in full here, supplements the previously published guideline Recommendations for Evaluation of Prosthetic Valves with Echocardiography and Doppler Ultrasound.

New medical technology offers the promise of improving patient care, as well as the potential for harm if caregivers are not sufficiently educated about its operation and use. Without a comprehensive approach, caregivers may learn how to use complex technology at the patient’s bedside, through trial and error, instruction manuals or informally from their colleagues. An article in AACN Advanced Critical Care describes how Memorial Hermann Health System in Houston developed an interdisciplinary fail-safe process to analyze and scale training for use of medical devices, with a risk assessment tool to predict the severity and frequency of potential harm to patients.

Radiological Society of North America (RSNA)

Society of Cardiovascular Computed Tomography (SCCT)

American Society of Echocardiography (ASE)

American College of Cardiology (ACC)

American College of Cardiology (ACC)

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.
A comparison for size with the first generation version of the Aortix device.

The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms. As one organ fails, it pushes the other further away from physiological norms. The implication is that the heart is not the sole offender in heart failure. In fact, in a study of more than 100,000 heart failure admissions, less than 10 percent of patients had normal renal function.[1]
 

Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now